var data={"title":"Bevacizumab (including biosimilars of bevacizumab): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bevacizumab (including biosimilars of bevacizumab): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5737?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bevacizumab (including biosimilars of bevacizumab): Patient drug information&quot;</a> and <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Bevacizumab (including biosimilars of bevacizumab): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708647\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">GI perforations:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The incidence of GI perforations, some fatal, in patients receiving bevacizumab products ranges from 0.3% to 3%. Discontinue bevacizumab products in patients with GI perforation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Surgery and wound healing complications:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in patients receiving bevacizumab products. Discontinue bevacizumab products in patients who develop wound healing complications that require medical intervention. Withhold bevacizumab products at least 28 days prior to elective surgery. Do not administer bevacizumab products for at least 28 days after surgery and until the surgical wound is fully healed.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hemorrhage:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe or fatal hemorrhage, including hemoptysis, GI bleeding, hematemesis, CNS hemorrhage, epistaxis, and vaginal bleeding, occurs up to 5-fold more frequently in patients receiving bevacizumab products. Do not administer bevacizumab products to patients with a recent history of hemoptysis. Discontinue in patients who develop grade 3 to 4 hemorrhage.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141002\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Avastin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422982\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Avastin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141022\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody;</li>\n      <li>\n        Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor;</li>\n      <li>\n        Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141004\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Do not administer bevacizumab products until at least 28 days after surgery and the wound is fully healed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical cancer, persistent/recurrent/metastatic (Avastin [bevacizumab], Mvasi [bevacizumab-awwb; biosimilar]):</b> IV: 15 mg/kg every 3 weeks (in combination with paclitaxel and either cisplatin or topotecan) until disease progression or unacceptable toxicity (Tewari 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic, in combination with fluorouracil-based chemotherapy (Avastin, Mvasi):</b> IV: 5 mg/kg every 2 weeks (in combination with bolus-IFL) <b>or</b> 10 mg/kg every 2 weeks (in combination with FOLFOX4)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic, following first-line therapy containing bevacizumab (Avastin, Mvasi):</b> IV: 5 mg/kg every 2 weeks <b>or</b> 7.5 mg/kg every 3 weeks (in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based regimen)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glioblastoma, recurrent or progressive </b>\n      <b>(Avastin, Mvasi):</b> IV: 10 mg/kg every 2 weeks as a single agent until disease progression or unacceptable toxicity <b>or</b> (off-label combination) 10 mg/kg every 2 weeks (in combination with irinotecan) until disease progression or unacceptable toxicity (Friedman 2009; Vredenburgh 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (nonsquamous cell histology), first-line therapy (Avastin, Mvasi):</b> IV: 15 mg/kg every 3 weeks (in combination with carboplatin and paclitaxel) for 6 cycles (Sandler 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label combinations:</i> 15 mg/kg every 3 weeks (in combination with pemetrexed and carboplatin) for up to 4 cycles (Patel 2013) <b>or</b> 7.5 or 15 mg/kg every 3 weeks (in combination with cisplatin and gemcitabine) for up to 6 cycles (Reck 2009; Reck 2010) <b>or</b> 7.5 mg/kg every 3 weeks (in combination with pemetrexed and cisplatin) for 4 cycles (Barlesi 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance therapy (off-label use):</i> 15 mg/kg every 3 weeks as a single agent (after 6 cycles of induction therapy with bevacizumab, carboplatin and paclitaxel); continue maintenance therapy until disease progression or unacceptable toxicity (Sandler 2006) <b>or</b> 15 mg/kg (in combination with pemetrexed) every 3 weeks (following 4 cycles of induction therapy with bevacizumab, pemetrexed, and carboplatin); continue until disease progression or unacceptable toxicity (Patel 2013) <b>or</b> 7.5 mg/kg (in combination with pemetrexed) every 3 weeks (following 4 cycles of induction therapy with bevacizumab, cisplatin and pemetrexed); continue until disease progression or unacceptable toxicity (Barlesi 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian (epithelial), fallopian tube, or primary peritoneal cancer (platinum-resistant recurrent) (Avastin):</b> IV: 10 mg/kg every 2 weeks (in combination with weekly paclitaxel, every 4 week doxorubicin [liposomal], or days 1, 8, and 15 topotecan) <b>or</b> 15 mg/kg every 3 weeks (in combination with every 3 week topotecan) (Pujade-Lauraine 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian (epithelial), fallopian tube, or primary peritoneal cancer (platinum-sensitive recurrent) (Avastin):</b> IV: 15 mg/kg every 3 weeks (in combination with carboplatin and gemcitabine for 6 to 10 cycles or with carboplatin and paclitaxel for 6 to 8 cycles) then continue with bevacizumab (monotherapy) until disease progression or unacceptable toxicity (Aghajanian 2012; Aghajanian 2015; Coleman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell cancer, metastatic (Avastin, Mvasi):</b> IV: 10 mg/kg every 2 weeks (in combination with interferon alfa) <b>or</b> (off-label dosing) 10 mg/kg every 2 weeks as monotherapy (Yang 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Age-related macular degeneration (off-label use/route):</b> Intravitreal: 1.25 mg (0.05 mL) monthly for 3 months, then may be given scheduled (monthly) or as needed based on monthly ophthalmologic assessment (Chakravarthy 2013; Martin 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, metastatic (off-label use):</b> IV: 10 mg/kg every 2 weeks (in combination with paclitaxel) (Miller 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic macular edema (off-label use/route):</b> Intravitreal: 1.25 mg (0.05 mL) initially; repeat every 4 weeks depending on ophthalmologic response (visual acuity or central subfield thickness assessment) (Wells 2015); refer to protocol and supplementary materials for additional dosage and administration details.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial cancer, recurrent or persistent (off-label use):</b> IV: 15 mg/kg every 3 weeks (as monotherapy) until disease progression or unacceptable toxicity (Aghajanian 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hereditary </b>\n      <b>hemorrhagic telangiectasia (off-label use): </b>IV: 5 mg/kg every 2 weeks for 6 doses (Dupuis-Girod 2012). Additional data may be necessary to further define the role of bevacizumab in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant pleural mesothelioma, unresectable (off-label use): </b>IV: 15 mg/kg every 3 weeks (in combination with pemetrexed and cisplatin) for up to 6 cycles, followed by bevacizumab maintenance therapy at 15 mg/kg once every 3 weeks until disease progression or unacceptable toxicity (Zalcman 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Soft tissue sarcoma, angiosarcoma, metastatic or locally advanced (off-label use):</b> IV: 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity (Agulnik 2013). Additional data may be necessary to further define the role of bevacizumab in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991321\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Renal impairment prior to treatment:</i> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Renal toxicity during treatment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nephrotic syndrome: Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Proteinuria &ge;2 g/24 hours in the absence of nephrotic syndrome: Withhold bevacizumab until proteinuria &lt;2 g/24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988665\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50753376\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Bevacizumab (including biosimilars of bevacizumab): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Do not administer bevacizumab products until at least 28 days after surgery and the wound is fully healed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gliomas, recurrent or progressive (off-label use; based on limited data): </b>Children and Adolescents: IV: 10 mg/kg every 2 weeks in combination with irinotecan (with or without temozolomide) (Kang 2008; Narayana 2010; Packer 2009; Parekh 2011). Additional data may be necessary to further define the role of bevacizumab in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Medulloblastoma, relapsed/refractory (off-label use; based on limited data): </b>Children: IV: 10 mg/kg every 2 weeks in combination with irinotecan (with or without temozolomide; with or without vincristine) (Aguilera 2011; Aguilera 2013). Additional data may be necessary to further define the role of bevacizumab in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Solid tumors, refractory (off-label use; based on limited data):</b> Children and Adolescents: IV: 5 to 10 mg/kg every 2 or 3 weeks (Benesch 2008). Additional data may be necessary to further define the role of bevacizumab in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51073558\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51073559\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141005\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141023\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV administration (systemic): There are no recommended dosage reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fistula (grade 4), tracheoesophageal fistula (any grade), fistula formation involving any internal organ: Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal perforation (any grade): Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Heart failure: Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemorrhage:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 or 4: Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemoptysis (recent history of &ge;2.5 mL): Withhold bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypertension:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypertensive crisis: Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypertensive encephalopathy: Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe hypertension: Withhold bevacizumab if not controlled with medical management; resume when hypertension is controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infusion reaction:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Clinically insignificant (mild): Decrease infusion rate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Clinically significant: Interrupt infusion; after symptoms resolve, resume at a decreased infusion rate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe: Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Posterior reversible encephalopathy syndrome (PRES): Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Thromboembolic events:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Arterial thromboembolism (severe): Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Venous thromboembolism (grade 4): Discontinue bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wound healing complications (requiring medical intervention or necrotizing fasciitis): Discontinue bevacizumab.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140982\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Avastin: 100 mg/4 mL (4 mL); 400 mg/16 mL (16 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140970\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50694899\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Bevacizumab-awwb (Mvasi) is approved as a biosimilar to bevacizumab (Avastin).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50606126\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Mvasi (bevacizumab-awwb): FDA approved September 2017; anticipated availability is currently unknown. Mvasi has been approved as a biosimilar, not as an interchangeable product. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140985\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse the initial dose over 90 minutes. The second infusion may be administered over 60 minutes if the initial infusion is well tolerated. The third and subsequent infusions may be administered over 30 minutes if the 60-minute infusion is well tolerated. After tolerance at the 90-, 60-, and 30-minute infusion rates has been established, some institutions use an off-label 10-minute infusion rate (0.5 mg/kg/minute) in adults for bevacizumab dosed at 5 mg/kg (Reidy 2007). In a study evaluating the safety of the 0.5 mg/kg/minute infusion rate, proteinuria, and hypertension incidences were not increased with the shorter infusion time (Shah 2013). Do not administer with dextrose solutions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Monitor closely during the infusion for signs/symptoms of an infusion reaction. Decrease infusion rate for mild (clinically insignificant) infusion reaction; interrupt infusion for clinically significant infusion reaction (after symptoms resolve, resume at a decreased infusion rate); discontinue bevacizumab for severe infusion reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravitreal injection (off-label use/route): Adequate local anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140984\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical cancer, persistent/recurrent/metastatic (Avastin [bevacizumab], Mvasi [bevacizumab-awwb; biosimilar]):</b> Treatment of persistent, recurrent, or metastatic cervical cancer (in combination with paclitaxel and either cisplatin or topotecan).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic (Avastin, Mvasi):</b> First- or second-line treatment of metastatic colorectal cancer (CRC) (in combination with fluorouracil-based chemotherapy); second-line treatment of metastatic CRC (in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy) after progression on a first-line treatment containing bevacizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Not indicated for the adjuvant treatment of colon cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glioblastoma, recurrent (Avastin):</b> Treatment of recurrent glioblastoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glioblastoma, progressive (Mvasi):</b> Treatment of glioblastoma (as a single agent) in patients with progressive disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer, nonsquamous (Avastin, Mvasi): </b> First-line treatment of unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer (NSCLC) (in combination with carboplatin and paclitaxel).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian (epithelial), fallopian tube, or primary peritoneal cancer (platinum-resistant recurrent) (Avastin<b>)</b>:</b> Treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with paclitaxel, doxorubicin [liposomal], or topotecan) in patients who received no more than 2 prior chemotherapy regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian (epithelial), fallopian tube, or primary peritoneal cancer (platinum-sensitive recurrent) (Avastin):</b> Treatment of platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine and then followed by single-agent bevacizumab).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell carcinoma, metastatic (Avastin, Mvasi):</b> Treatment of metastatic renal cell carcinoma (RCC) (in combination with interferon alfa).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475200\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Age-related macular degeneration; Breast cancer, metastatic; Diabetic macular edema; Endometrial cancer, recurrent or persistent; Gliomas (recurrent or progressive) (pediatrics); Hereditary hemorrhagic telangiectasia; Malignant pleural mesothelioma (unresectable); Medulloblastoma (relapsed or refractory); Soft tissue sarcoma, angiosarcoma; Soft tissue sarcoma, hemangiopericytoma; Solid tumors, refractory (pediatrics)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2110715\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Avastin may be confused with Astelin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bevacizumab may be confused with bevacizumab-awwb, bezlotoxumab, brentuximab, cetuximab, ranibizumab, riTUXimab</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Avastin [US, Canada, and multiple international markets] may be confused with Avaxim, a brand name for hepatitis A vaccine [Canada and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140975\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Percentages reported as monotherapy and as part of combination chemotherapy regimens. Some studies only reported hematologic toxicities grades &ge;4 and nonhematologic toxicities grades &ge;3.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (19% to 42%), venous thromboembolism (secondary: 21%; with oral anticoagulants), peripheral edema (15%), hypotension (7% to 15%), venous thromboembolism (8% to 14%), arterial thrombosis (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (33% to 82%), pain (8% to 62%), headache (22% to 49%), dizziness (13% to 26%), insomnia (21%), taste disorder (14% to 21%), peripheral sensory neuropathy (17% to 18%), anxiety (17%), myasthenia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (6% to 32%), exfoliative dermatitis (23%), palmar-plantar erythrodysesthesia (11%), xeroderma (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Ovarian failure (34%), hyperglycemia (26% to 31%), hypomagnesemia (24% to 27%), weight loss (15% to 21%), hyponatremia (17% to 19%), hypoalbuminemia (11% to 16%), hypocalcemia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (72%), abdominal pain (33% to 61%), vomiting (33% to 52%), anorexia (35% to 43%), constipation (40%), diarrhea (21% to 39%), decreased appetite (34% to 35%), stomatitis (15% to 33%), gastrointestinal hemorrhage (19% to 24%), dyspepsia (17% to 24%), mucosal inflammation (13% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Proteinuria (4% to 36%; median onset: 5.6 months; median time to resolution: 6.1 months), urinary tract infection (22%), pelvic pain (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (5% to 58%; grade 3/4: 40%), hemorrhage (40%; grades 3/4: &le;7%), leukopenia (grades 3/4: 37%), pulmonary hemorrhage (4% to 31%), neutropenia (12%; grades &ge;3: 8% to 27%, grade 4: 27%), bruise (17%), lymphocytopenia (12%; grades 3/4: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (55%; serious: 7% to 14%; pneumonia, catheter infection, or wound infection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (28% to 45%), myalgia (19% to 29%), limb pain (25%), back pain (12% to 21%), dysarthria (8% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (13% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (17% to 55%), upper respiratory tract infection (40% to 47%), cough (26% to 30%), dyspnea (25% to 30%), allergic rhinitis (17%), oropharyngeal pain (16%), sinusitis (7% to 15%), nasal sign &amp; symptoms (mucosal disorder: 14%), rhinitis (3% to &gt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Postoperative wound complication (including dehiscence, 1% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Thrombosis (8% to 10%), deep vein thrombosis (6% to 9%), chest pain (8%), intra-abdominal thrombosis (venous, grades 3/4: 3%), syncope (grades 3/4: 3%), left ventricular dysfunction (grades 3/4: 1%), pulmonary embolism (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Voice disorder (5% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Nail disease (10%), dermal ulcer (6%), cellulitis (grades 3/4: 3%), acne vulgaris (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (grades 3/4: 4% to 10%), hyperkalemia (9%), hypokalemia (grades 3/4: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Hemorrhoids (8%), xerostomia (4% to 7%), gingival hemorrhage (minor, 2% to 7%), rectal pain (6%), colitis (1% to 6%), intestinal obstruction (grades 3/4: 4%), gastrointestinal perforation (&le;3%), gastroesophageal reflux disease (2%), gingivitis (2%), oral mucosa ulcer (2%), gastrointestinal fistula (&le;2%), gastritis (1%), gingival pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal hemorrhage (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Febrile neutropenia (5%), neutropenic infection (grades 3/4: 5%), hemorrhage (CNS; 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess (tooth, 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (grades 3/4: 10%), neck pain (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus (2%), deafness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinorrhea (10%), nasal congestion (8%), pneumonitis (grades 3/4: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fistula (gastrointestinal-vaginal; 8%), fistula (anal; 6%), infusion related reaction (&lt;3%), fistula (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, anastomotic ulcer, angina pectoris, antibody development (anti-bevacizumab and neutralizing), bladder fistula, bronchopleural fistula, cerebral infarction, conjunctival hemorrhage, endophthalmitis (infectious and sterile), eye discomfort, eye pain, fistula of bile duct, fulminant necrotizing fasciitis, gallbladder perforation, gastrointestinal ulcer, hemolytic anemia (microangiopathic; when used in combination with sunitinib), hemoptysis, hemorrhagic stroke, hypersensitivity, hypertensive crisis, hypertensive encephalopathy, increased intraocular pressure, inflammation of anterior segment of eye (toxic anterior segment syndrome) (Sato 2010), intestinal necrosis, intraocular inflammation (iritis, vitritis), mesenteric thrombosis, myocardial infarction, nasal septum perforation, nephrotic syndrome, ocular hyperemia, osteonecrosis of the jaw, pancytopenia, permanent vision loss, polyserositis, pulmonary hypertension, rectal fistula, renal failure, renal fistula, renal thrombotic microangiopathy, retinal detachment, retinal hemorrhage, reversible posterior leukoencephalopathy syndrome, sepsis, tracheoesophageal fistula, transient ischemic attacks, vaginal fistula, visual disturbance, vitreous hemorrhage, vitreous opacity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140988\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to bevacizumab, any component of the formulation, Chinese hamster ovary cell products or other recombinant human or humanized antibodies; untreated CNS metastases</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140973\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal perforation/fistula: <b>[US Boxed Warning]: GI perforation, (sometimes fatal) in patients receiving bevacizumab products ranges from 0.3% to 3%; discontinue bevacizumab products in patients with GI perforation.</b> A higher incidence of GI perforation is associated with a history of prior pelvic radiation. Most cases of GI perforation occurred within 50 days of the first bevacizumab dose. Perforation may be complicated by intra-abdominal abscess, fistula formation, and/or diverting ostomy requirement. Serious fistulae (including tracheoesophageal, bronchopleural, biliary, vaginal, renal, and bladder fistulas) have been reported at a higher incidence in patients receiving bevacizumab products (compared to patients receiving chemotherapy), with the highest incidence occurring in patients with cervical cancer. Most fistulae occurred within 6 months of the first bevacizumab dose. Patients who develop gastrointestinal vaginal fistula may also have bowel obstruction which requires surgical intervention and diverting ostomy. Avoid bevacizumab products in patients with ovarian cancer with evidence of recto-sigmoid involvement (by pelvic examination) or bowel involvement (on CT scan), or clinical symptoms of bowel obstruction. Discontinue in patients who develop gastrointestinal perforation, tracheoesophageal fistula, any grade 4 fistula, or fistula formation involving any internal organ.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, bevacizumab has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]). Bevacizumab is not indicated for use in combination with anthracycline-based chemotherapy. The incidence of grade &ge;3 left ventricular dysfunction was higher in patients receiving bevacizumab with chemotherapy compared to patients who received chemotherapy alone (1% vs 0.6%). Among patients who received prior anthracycline therapy, the incidence of HF was higher in patients receiving bevacizumab with chemotherapy, compared to patients who received chemotherapy alone (4% vs 0.6%). In previously untreated patients with hematologic malignancy, the incidence of HF and left ventricular ejection fraction (LVEF) decline were increased in patients receiving bevacizumab with anthracycline-based chemotherapy (compared to patients receiving anthracycline-based chemotherapy alone). The proportion of patients with a LVEF decline (from baseline) of &ge;20% or a decline from baseline of 10% to &lt;50%, was higher in patients receiving bevacizumab with chemotherapy compared to patients receiving chemotherapy alone (10% vs 5%). Time to onset of left ventricular dysfunction or HF was 1 to 6 months after the first bevacizumab dose in most patients; HF resolved in nearly two-thirds of patients. Discontinue bevacizumab products in patients who develop HF.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: <b>[US Boxed Warning]: Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, hematemesis, central nervous system hemorrhage, epistaxis, and vaginal bleeding occur up to 5-fold more frequently in patients receiving bevacizumab products. </b><b>Do not administer bevacizumab products to patients with a recent history of hemoptysis (&ge;2.5 mL blood). Discontinue in patients who develop grade 3 to 4 hemorrhage.</b> Serious or fatal pulmonary hemorrhage has been reported in nearly one-third of patients receiving bevacizumab plus chemotherapy for non-small cell lung cancer (NSCLC) with squamous cell histology (not an FDA-approved indication), as well as a small portion of NSCLC with nonsquamous histology; while no cases occurred in patients receiving chemotherapy alone. Minor hemorrhages, including grade 1 epistaxis may commonly occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Bevacizumab may cause and/or worsen hypertension. The incidence of severe hypertension in increased with bevacizumab products. Manage hypertension with antihypertensive therapy. Monitor BP every 2 to 3 weeks during bevacizumab treatment and regularly after discontinuation if bevacizumab-induced hypertension occurs or worsens. Withhold bevacizumab treatment in patients with severe hypertension that is uncontrolled with medical management (resume bevacizumab after blood pressure is controlled). Discontinue bevacizumab products in patients who experience a hypertensive crisis or hypertensive encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Infusion reactions (eg, hypertension, hypertensive crisis [associated with neurologic signs/symptoms], wheezing, oxygen desaturation, hypersensitivity [grade 3], chest pain, rigors, headache, diaphoresis) may occur with the first infusion (uncommon); severe reactions were rare. Decrease the infusion rate for mild/clinically insignificant infusion reactions. Interrupt infusion for clinically significant infusion reactions and consider resuming at a slower rate following resolution. Discontinue bevacizumab for severe infusion reaction and administer appropriate medical therapy (eg, epinephrine, corticosteroids, IV antihistamines, bronchodilators, and/or oxygen).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mortality: Bevacizumab, in combination with chemotherapy (or biologic therapy), is associated with an increased risk of treatment-related mortality; a higher risk of fatal adverse events was identified in a meta-analysis of 16 trials in which bevacizumab was used for the treatment of various cancers (breast cancer, colorectal cancer, NSCLC, pancreatic cancer, prostate cancer, and renal cell cancer) and compared to chemotherapy alone (Ranpura 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Necrotizing fasciitis: Cases of necrotizing fasciitis, including fatalities, have been reported in patients receiving bevacizumab, usually secondary to wound healing complications, GI perforation or fistula formation. Discontinue in patients who develop necrotizing fasciitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular adverse events: Serious eye infections and vision loss due to endophthalmitis have been reported from intravitreal administration (off-label use/route).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw (ONJ): According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), medication-related osteonecrosis of the jaw (MRONJ) has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy. Antiangiogenic agents, when given concomitantly with antiresorptive agents, are associated with an increased risk of ONJ. Other risk factors for MRONJ include dentoalveolar surgery (eg, tooth extraction, dental implants), preexisting inflammatory dental disease, and concomitant corticosteroid use. The AAOMS suggests that if medically permissible, initiation of antiangiogenic agents for cancer therapy should be delayed until optimal dental health is attained (if extractions are required, antiangiogenesis therapy should delayed until the extraction site has mucosalized or until after adequate osseous healing). Once antiangiogenic therapy for oncologic disease is initiated, procedures that involve direct osseous injury and placement of dental implants should be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). Cases of non-mandibular ONJ has also been reported in pediatric patients who have received bevacizumab (bevacizumab is not approved for use in pediatric patients).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian failure: In premenopausal women with solid tumors receiving adjuvant therapy, the incidence of ovarian failure was 34% for bevacizumab with chemotherapy versus 2% for chemotherapy alone. Recovery of ovarian function (resumption of menses, positive serum &beta;-HCG pregnancy test, or FSH level &lt;30 mIU/mL) at all time points in the post-treatment period after bevacizumab discontinuation was demonstrated in approximately one-fifth of females who received bevacizumab. The long-term effects of bevacizumab on fertility are unknown. Females of reproductive potential should be informed of the potential risk of ovarian failure prior to bevacizumab initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Posterior reversible encephalopathy syndrome: Cases of posterior reversible encephalopathy syndrome (PRES) have been reported. Symptoms (which include headache, seizure, confusion, lethargy, blindness and/or other vision, or neurologic disturbances) may occur from 16 hours to 1 year after treatment initiation. PRES may also be associated with mild to severe hypertension. MRI is necessary for confirmation of PRES diagnosis. Discontinue bevacizumab products in patients who develop PRES. Resolution of symptoms usually occurs within days after discontinuation; however, neurologic sequelae may remain. The safety of treatment reinitiation after PRES is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proteinuria/nephrotic syndrome: Bevacizumab products are associated with an increased incidence and severity of proteinuria. Grade 3 (urine dipstick 4+ or &gt;3.5 g protein/24 hours) and grade 4 (nephrotic syndrome) proteinuria have occurred in clinical studies. The overall incidence of all grades of proteinuria in one study was 20%. The median onset of proteinuria was 5.6 months (range: 0.5 to 37 months) after bevacizumab initiation and the median time to resolution was ~6 months. Proteinuria remained unresolved in 40% of patients after median follow-up of 11.2 months and required bevacizumab discontinuation in nearly one-third of patients. A pooled analysis from 7 studies found that 5% of patients receiving bevacizumab products in combination with chemotherapy experienced grades 2 to 4 proteinuria (urine dipstick 2+ or &gt;1 g protein/24 hours or nephrotic syndrome), which resolved in nearly three-fourths of patients; bevacizumab was reinitiated in 42% of patients, although nearly half of patients who reinitiated experienced recurrent grades 2 to 4 proteinuria. Nephrotic syndrome has occurred (rarely) in patients receiving bevacizumab, sometimes with fatal outcome. In some cases, kidney biopsy of patients with proteinuria demonstrated findings consistent with thrombotic microangiopathy. A large retrospective analysis comparing bevacizumab with chemotherapy to chemotherapy alone found higher rates of serum creatinine elevations (1.5 to 1.9 times baseline) in patients who received bevacizumab; serum creatinine did not return to baseline in approximately one-third of patients who received bevacizumab. Monitor proteinuria (by serial dipstick urine analysis) for proteinuria development or worsening of proteinuria throughout bevacizumab therapy. Further assess with a 24-hour urine collection for &ge;2+ urine dipstick readings. Withhold bevacizumab for proteinuria &ge;2 g/24 hours; resume when &lt;2 g/24 hours. Discontinue bevacizumab products in patients who develop nephrotic syndrome. Urine protein/creatinine ratio (UPCR) does not appear to correlate with 24-hour urine protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Bevacizumab products are associated with an increased incidence of arterial thromboembolic events (ATE), including cerebral infarction, stroke, MI, TIA, angina, and other ATEs, when used in combination with chemotherapy. The highest incidence of ATE occurred in patients with glioblastoma. History of ATE, diabetes, or &ge;65 years of age may present an even greater risk. Although patients with cancer are already at risk for VTE, a meta-analysis of 15 controlled trials has demonstrated an increased risk for VTE in patients who received bevacizumab (Nalluri 2008). Patients receiving bevacizumab plus chemotherapy had a higher incidence of grade 3 or higher VTE compared to those patients who received chemotherapy alone. Discontinue bevacizumab in patients with severe ATE or grade 4 VTE, including pulmonary embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound healing complications: <b>[US Boxed Warning]: The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in patients receiving bevacizumab products; discontinue in </b><b>patients who develop wound healing complications that require medical intervention. Withhold bevacizumab products at least 28 days prior to elective surgery. Do not administer bevacizumab products for at least 28 days after surgery and until the surgical<b> wound is fully healed. </b></b>In a controlled study in which bevacizumab was not administered within 28 days of major surgical procedures, the incidence of wound healing complications (including serious/fatal complications) was higher in patients with mCRC who underwent surgery while receiving bevacizumab compared to patients who did not receive bevacizumab. In a controlled clinical study in patients with relapsed or recurrent glioblastoma, the incidence of wound healing events was higher in patients who received bevacizumab compared to patients who did not receive bevacizumab. In a retrospective review of central venous access device placements (a minor procedure), a greater risk of wound dehiscence was observed when port placement and bevacizumab administration were separated by &lt;14 days (Erinjeri 2011). If possible, it may be more appropriate to wait until at least 6 to 8 weeks after bevacizumab discontinuation for major surgical procedures (Cortes 2012; Gordon 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: An increase in diastolic and systolic blood pressures were noted in a retrospective review of patients with renal insufficiency (CrCl &le;60 mL/minute) who received bevacizumab for renal cell cancer (Gupta 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients &ge;65 years of age have an increased incidence of arterial thrombotic events.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298861\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140976\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8683&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anthracyclines: Bevacizumab may enhance the cardiotoxic effect of Anthracyclines. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: Bevacizumab may enhance the adverse/toxic effect of SORAfenib. Specifically, the risk for hand-foot skin reaction may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: May enhance the adverse/toxic effect of Bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of SUNItinib.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140991\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on findings in animal reproduction studies and on the mechanism of action, bevacizumab may cause fetal harm if administered to a pregnant woman. Information from postmarketing reports following exposure in pregnancy is limited. Women of reproductive potential should use effective contraception during therapy and for 6 months following the last bevacizumab dose. Bevacizumab treatment may also increase the risk of ovarian failure and impair fertility; long term effects on fertility are not known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140992\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if bevacizumab is present in breast milk. Immunoglobulins are excreted in breast milk, and it is assumed that bevacizumab may appear in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment and for 6 months following the last dose of bevacizumab products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140980\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor for proteinuria/nephrotic syndrome with urine dipstick; collect 24-hour urine in patients with &ge;2+ reading. Monitor blood pressure every 2 to 3 weeks; more frequently if hypertension develops during therapy; continue to monitor blood pressure after discontinuing due to bevacizumab-induced hypertension. Monitor closely during the infusion for signs/symptoms of an infusion reaction. Monitor for signs/symptoms of gastrointestinal perforation or fistula (including abdominal pain, constipation, vomiting, and fever), bleeding (including epistaxis, hemoptysis, gastrointestinal, and/or CNS bleeding), and thromboembolism (arterial and venous).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AMD (off-label use): Monitor intraocular pressure and retinal artery perfusion. Monitor for signs/symptoms of infectious endophthalmitis and retinal detachment (AAO 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diabetic macular edema (off-label use): Monitor visual acuity, central subfield thickness, and intraocular pressure; monitor for signs/symptoms of infectious endophthalmitis, cataracts, and retinal detachment (AAO 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hereditary hemorrhagic telangiectasia (off-label use): Cardiac output measurements and liver radiologic response (via ultrasound and hepatic CT exams) prior to initial treatment and at 3 and 6 months following the first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140972\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bevacizumab is a recombinant, humanized monoclonal antibody which binds to, and neutralizes, vascular endothelial growth factor (VEGF), preventing its association with endothelial receptors, Flt-1 and KDR. VEGF binding initiates angiogenesis (endothelial proliferation and the formation of new blood vessels). The inhibition of microvascular growth is believed to retard the growth of all tissues (including metastatic tissue).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140987\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: CV% central volume: 2.9 (22%) L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pediatric patients (age: 1 to 21 years): Median: 11.8 days (range: 4.4 to 14.6 days) (Glade Bender 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: ~20 days (range: 11 to 50 days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intravitreal: ~5 to 10 days (Bakri 2007; Krohne 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51154010\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gender: Men had a higher clearance and larger volume of distribution in the central compartment when compared with women. There is no evidence that this difference decreases the efficacy of bevacizumab in men.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tumor burden: Patients with a higher tumor burden had a higher clearance of bevacizumab compared with patients who had a tumor burden below the median. There is no evidence suggesting that this difference leads to decreased efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140990\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Avastin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/4 mL (4 mL): $933.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/16 mL (16 mL): $3,732.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140993\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Avastin (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VN);</li>\n      <li>Avastyn (UA);</li>\n      <li>Bevastim (BD);</li>\n      <li>Bivastin (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22529265\"></a>Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. <i>J Clin Oncol.</i> 2012;30(17):2039-2045.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/22529265/pubmed\" target=\"_blank\" id=\"22529265\">22529265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. <i>Gynecol Oncol</i>. 2015;139(1):10-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/26271155/pubmed\" target=\"_blank\" id=\"26271155\">26271155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21537039\"></a>Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. <i>J Clin Oncol</i>. 2011;29(16):2259-2265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21537039/pubmed\" target=\"_blank\" id=\"21537039\">21537039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21072819\"></a>Aguilera DG, Goldman S, Fangusaro J. Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma. <i>Pediatr Blood Cancer</i>. 2011;56:491-494. doi: 10.1002/pbc.22868.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21072819/pubmed\" target=\"_blank\" id=\"21072819\">21072819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23296323\"></a>Aguilera D, Mazewskli C, Fangusaro J, et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. <i>Childs Nerv Syst</i>. 2013;29:589-596. doi: 10.1007/s00381-012-2013-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/23296323/pubmed\" target=\"_blank\" id=\"23296323\">23296323</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22910841\"></a>Agulnik M, Yarber JL, Okuno SH, et al. An Open-Label, Multicenter, Phase II Study of Bevacizumab for the Treatment of Angiosarcoma and Epithelioid Hemangioendotheliomas. <i>Ann Oncol.</i> 2013;24(1):257-263.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/22910841/pubmed\" target=\"_blank\" id=\"22910841\">22910841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19414665\"></a>Allegra CJ, Yothers G, O'Connell MJ, et al. Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer. <i>J Clin Oncol.</i> 2009;27(20):3385-3390.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19414665/pubmed\" target=\"_blank\" id=\"19414665\">19414665</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      American Academy of Ophthalmology. Diabetic Retinopathy. https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2016. Accessed November 14, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Ophthalmology. Age-related macular degeneration preferred practice pattern guidelines. http://one.aao.org/preferred-practice-pattern/agerelated-macular-degeneration-ppp--september-200. Updated 2011. Accessed May 12, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avastin (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avastin (bevacizumab) [product monograph]. Mississauga, ON, Canada: Hoffmann-La Roche; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-Foot Skin Reaction Increases With Cumulative Sorafenib Dose and With Combination Anti-Vascular Endothelial Growth Factor Therapy. <i>Clin Cancer Res.</i> 2009;15(4):1411-1416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19228742/pubmed\" target=\"_blank\" id=\"19228742\">19228742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). <i>Ophthalmology</i>, 2007;114(5):855-859.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/17467524/pubmed\" target=\"_blank\" id=\"17467524\">17467524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bansal N and Hoffman M. Bladder Perforation in a Patient With Recurrent Epithelial Ovarian Cancer After Treatment With Bevacizumab. <i>Gynecol Oncol.</i> 2011;120(2):313-314.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21055796/pubmed\" target=\"_blank\" id=\"21055796\">21055796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). <i>J Clin Oncol</i>. 2013;31(24):3004-3011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/23835708/pubmed\" target=\"_blank\" id=\"23835708\">23835708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18056650\"></a>Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. <i>Ann Oncol.</i> 2008;19(4):807-813. doi: 10.1093/annonc/mdm510.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18056650/pubmed\" target=\"_blank\" id=\"18056650\">18056650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bracarda S, Bellmunt J, Melichar B, et al. Overall Survival in Patients With Metastatic Renal Cell Carcinoma Initially Treated With Bevacizumab Plus Interferon-&alpha;2a and Subsequent Therapy With Tyrosine Kinase Inhibitors: A Retrospective Analysis of the Phase III AVOREN Trial. <i>BJU Int.</i> 2011;107(2):214-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/20942831/pubmed\" target=\"_blank\" id=\"20942831\">20942831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22204724\"></a>Burger RA, Brady MF, Bookman MA, et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. <i>N Engl J Med. </i> 2011;365(26):2473-2483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/22204724/pubmed\" target=\"_blank\" id=\"22204724\">22204724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burger RA, Sill MW, Monk BJ, et al. Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study. <i>J Clin Oncol. </i>2007;25(33):5165-5171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18024863/pubmed\" target=\"_blank\" id=\"18024863\">18024863</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18024865\"></a>Cannistra SA, Matulonis UA, Penson RT, et al. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer. <i>J Clin Oncol.</i> 2007;25(33):5180-5186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18024865/pubmed\" target=\"_blank\" id=\"18024865\">18024865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23870813\"></a>Chakravarthy U, Harding SP, Rogers CA, et al; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. <i>Lancet</i>. 2013;382(9900):1258-1267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/23870813/pubmed\" target=\"_blank\" id=\"23870813\">23870813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Christodoulou C, Pervena A, Klouvas G, et al. Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently Than Bisphosphonates Alone. <i>Oncology.</i> 2009;76(3):209-211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19212145/pubmed\" target=\"_blank\" id=\"19212145\">19212145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloughesy TF, Prados MD, Wen PY, et al. A Phase II, Randomized, Non-Comparative Clinical Trial of the Effect of Bevacizumab (BV) Alone or in Combination With Irinotecan (CPT) on 6-Month Progression Free Survival (PFS6) in Recurrent, Treatment-Refractory Glioblastoma (GBM). <i>J Clin Oncol.</i> 2008;26(supp):2010B [abstract 2010b from 2008 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coleman RL, Brady MF, Herzog TJ, et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). Scientific Plenary #3 Presented at the 2015 Annual Meeting for Women's Cancers. March 28, 2015. Chicago, IL.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22196033\"></a>Cort&eacute;s J, Caralt M, Delaloge S, et al. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. <i>Eur J Cancer</i>. 2012;48(4):475-481.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/22196033/pubmed\" target=\"_blank\" id=\"22196033\">22196033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22396517\"></a>Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. <i>JAMA</i>. 2012;307(9):948-955.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/22396517/pubmed\" target=\"_blank\" id=\"22396517\">22396517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erinjeri JP, Fong AJ, Kemeny NE, et al, &ldquo;Timing of Administration of Bevacizumab Chemotherapy Affects Wound Healing After Chest Wall Port Placement,&rdquo; <i>Cancer</i>, 2011, 117(6):1296-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21381016/pubmed\" target=\"_blank\" id=\"21381016\">21381016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18156031\"></a>Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab Plus Interferon Alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial. <i>Lancet. </i>2007;370(9605):2103-2111.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18156031/pubmed\" target=\"_blank\" id=\"18156031\">18156031</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18711196\"></a>Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. <i>J Clin Oncol.</i> 2008;26(24):4037-4038.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18711196/pubmed\" target=\"_blank\" id=\"18711196\">18711196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19224847\"></a>Feldman DR, Baum MS, Ginsberg MS, et al. Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>J Clin Oncol. </i>2009;27(9):1432-1439.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19224847/pubmed\" target=\"_blank\" id=\"19224847\">19224847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feldman DR, Ginsberg MS, Baum M, et al. Phase I Trial of Bevacizumab Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>J Clin Oncol.</i> 2008;26(supp):5100 [abstract 5100 from 2008 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. <i>J Clin Oncol</i>. 2009;27(28):4733-4740.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/1972097/pubmed\" target=\"_blank\" id=\"1972097\">1972097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18202416\"></a>Glade Bender JL, Adamson PC, Reid JM, et al. Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. <i>J Clin Oncol.</i> 2008;26(3):399-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18202416/pubmed\" target=\"_blank\" id=\"18202416\">18202416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16510760\"></a>Glusker P, Recht L, Lane B. Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab. <i>N Engl J Med.</i> 2006;354(9):980-982.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/16510760/pubmed\" target=\"_blank\" id=\"16510760\">16510760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19461291\"></a>Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. <i>Ann Plast Surg</i>. 2009;62(6):707-709.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19461291/pubmed\" target=\"_blank\" id=\"19461291\">19461291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18977851\"></a>Greuter S, Schmid F, Ruhstaller T, et al. Bevacizumab-associated osteonecrosis of the jaw. <i>Ann Oncol.</i> 2008;19(12):2091-2092.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18977851/pubmed\" target=\"_blank\" id=\"18977851\">18977851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19720913\"></a>Gray R, Bhattacharya S, Bowden C, et al. Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer. <i>J Clin Oncol. </i>2009;27(30):4966-4972.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19720913/pubmed\" target=\"_blank\" id=\"19720913\">19720913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21799472\"></a>Gupta S, Parsa VB, Heilbrun LK, et al. Safety and Efficacy of Molecularly Targeted Agents in Patients With Metastatic Kidney Cancer With Renal Dysfunction. <i>Anticancer Drugs.</i> 2011;22(8):794-800.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21799472/pubmed\" target=\"_blank\" id=\"21799472\">21799472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2017; 35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson DH, Fehrenbacher L, Novotny WF, et al, &ldquo;Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,&rdquo; <i>J Clin Oncol</i>, 2004, 22(11):2184-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/15169807/pubmed\" target=\"_blank\" id=\"15169807\">15169807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18438609\"></a>Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. <i>J Neurooncol</i>. 2008;89:113-118. doi: 10.1007/s11060-008-9599-0.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18438609/pubmed\" target=\"_blank\" id=\"18438609\">18438609</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kreisl TN, Kim L, Moore K, et al. Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma. <i>J Clin Oncol.</i> 2009;27(5):740-745.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19114704/pubmed\" target=\"_blank\" id=\"19114704\">19114704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18635152\"></a>Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. <i>Am J Ophthalmol</i>. 2008;146(4):508-512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18635152/pubmed\" target=\"_blank\" id=\"18635152\">18635152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leighl NB, Bennouna J, Yi J, et al. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. <i>Br J Cancer. </i>2011;104(3):413-418.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21245868/pubmed\" target=\"_blank\" id=\"21245868\">21245868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20978447\"></a>Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL). <i>J Thorac Oncol.</i> 2010;5(12):1970-1976.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/20978447/pubmed\" target=\"_blank\" id=\"20978447\">20978447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lou E, Turner S, Sumrall A, et al, &ldquo;Bevacizumab-Induced Reversible Posterior Leukoencephalopathy Syndrome and Successful Retreatment in a Patient With Glioblastoma,&rdquo; <i>J Clin Oncol</i>, 2011, 29(28):e739-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21900098/pubmed\" target=\"_blank\" id=\"21900098\">21900098</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22555112\"></a>Martin DF, Maguire MG, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. <i>Ophthalmology</i>. 2012;119(7):1388-1398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/22555112/pubmed\" target=\"_blank\" id=\"22555112\">22555112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2015;33(30):3488-3515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/26324367/pubmed\" target=\"_blank\" id=\"26324367\">26324367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miles D, Chan A, Dirix LY, et al, &quot;Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2010, 28(20):3239-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/20498403/pubmed\" target=\"_blank\" id=\"20498403\">20498403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller KD, &quot;E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer,&quot; <i>Clin Breast Cancer</i>, 2003, 3(6):421-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/12636887/pubmed\" target=\"_blank\" id=\"12636887\">12636887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller KD, Chap LI, Holmes FA, et al, &quot;Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer,&quot; <i>J Clin Oncol</i>, 2005, 23(4):792-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/15681523/pubmed\" target=\"_blank\" id=\"15681523\">15681523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18160686\"></a>Miller K, Wang M, Gralow J, et al, &ldquo;Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer,&rdquo; <i>N Engl J Med</i>, 2007, 357(26):2666-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18160686/pubmed\" target=\"_blank\" id=\"18160686\">18160686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monk BJ, Choi DC, Pugmire G, et al, &ldquo;Activity of Bevacizumab (rhuMAB VEGF) in Advanced Refractory Epithelial Ovarian Cancer,&rdquo; <i>Gynecol Oncol</i>, 2005, 96(3):902-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/15721449/pubmed\" target=\"_blank\" id=\"15721449\">15721449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monk BJ, Sill MW, Burger RA, et al, &quot;Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study,&quot; <i>J Clin Oncol</i>, 2009, 27(7):1069-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19139430/pubmed\" target=\"_blank\" id=\"19139430\">19139430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mvasi (bevacizumab-awwb) [prescribing information]. Thousand Oaks, CA: Amgen Inc; September 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19139430/pubmed\" target=\"_blank\" id=\"19139430\">19139430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nalluri SR, Chu D, Keresztes R, et al, &ldquo;Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-Analysis,&rdquo; <i>JAMA</i>, 2008, 300(19): 2277-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19017914/pubmed\" target=\"_blank\" id=\"19017914\">19017914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20363768\"></a>Narayana A, Kunnakkat S, Chacko-Mathew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. <i>Neuro Oncology</i>. 2010;12(9):985-990. doi: 10.1093/neuonc/noq033.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/20363768/pubmed\" target=\"_blank\" id=\"20363768\">20363768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozcan C, Wong SJ, and Hari P, &ldquo;Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab,&rdquo; <i>N Engl J Med</i>, 2006, 354(9):981-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/16514715/pubmed\" target=\"_blank\" id=\"16514715\">16514715</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19165892\"></a>Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. <i>Pediatr Blood Cancer</i>. 2009;52:791-795. doi: 10.1002/pbc.21935.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19165892/pubmed\" target=\"_blank\" id=\"19165892\">19165892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27400984\"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69. doi: 10.1161/CIR.0000000000000426.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21038110\"></a>Parekh C, Jubran R, Erdreich-Epstein A, et al. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. <i>J Neurooncol</i>. 2011;103: 673-680. doi: 10.1007/s11060-010-0444-x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21038110/pubmed\" target=\"_blank\" id=\"21038110\">21038110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21480200\"></a>Park MS, Patel SR, Ludwig JA, et al, &ldquo;Activity of Temozolomide and Bevacizumab in the Treatment of Locally Advanced, Recurrent, and Metastatic Hemangiopericytoma and Malignant Solitary Fibrous Tumor,&rdquo; <i>Cancer</i>, 2011, 117(21):4939-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21480200/pubmed\" target=\"_blank\" id=\"21480200\">21480200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. <i>J Clin Oncol</i>. 2013;31(34):4349-4357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/24145346/pubmed\" target=\"_blank\" id=\"24145346\">24145346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perren TJ, Swart AM, Pfisterer J, et al, &ldquo;A Phase 3 Trial of Bevacizumab in Ovarian Cancer,&rdquo; <i>N Engl J Med</i>, 2011, 365(26):2484-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/22204725/pubmed\" target=\"_blank\" id=\"22204725\">22204725</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polyzos A, Kalbakis K, Kentepozidis N, et al, &ldquo;Salvage Treatment In Metastatic Breast Cancer With Weekly Paclitaxel and Bevacizumab,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2011, 68(1):217-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/20922389/pubmed\" target=\"_blank\" id=\"20922389\">20922389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. <i>J Clin Oncol</i>. 2014;32(13):1302-1308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/24637997/pubmed\" target=\"_blank\" id=\"24637997\">24637997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ranpura V, Hapani S, and Wu S, &ldquo;Treatment-Related Mortality With Bevacizumab in Cancer Patients,&rdquo; <i>JAMA</i>, 2011, 305(5):487-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/21285426/pubmed\" target=\"_blank\" id=\"21285426\">21285426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reck M, von Pawel J, Zatloukal P, et al; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). <i>Ann Oncol</i>. 2010;21(9):1804-1809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/20150572/pubmed\" target=\"_blank\" id=\"20150572\">20150572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reck M, von Pawel J, Zatloukal P, et al, &ldquo;Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAil,&rdquo; <i>J Clin Oncol</i>, 2009, 27(8):1227-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/19188680/pubmed\" target=\"_blank\" id=\"19188680\">19188680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reidy DL, Chung KY, Timoney JP, et al, &ldquo;Bevacizumab 5 mg/kg Can be Infused Safely over 10 minutes,&rdquo; <i>J Clin Oncol</i>, 2007, 25(19):2691-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/17602073/pubmed\" target=\"_blank\" id=\"17602073\">17602073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rini BI, Halabi S, Rosenberg JE, et al, &ldquo;Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206,&rdquo; <i>J Clin Oncol</i>, 2008, 26(33):5422-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18936475/pubmed\" target=\"_blank\" id=\"18936475\">18936475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robert NJ, Dieras V, Glaspy J, et al, &ldquo;RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab (B) for First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC),&rdquo; <i>J Clin Oncol</i>, 2009, 27(15s):1005 [abstract 1005 from 2009 ASCO Annual Meeting]</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/25234529/pubmed\" target=\"_blank\" id=\"25234529\">25234529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saltz LB, Clarke S, D&iacute;az-Rubio E, et al, &ldquo;Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,&rdquo; <i>J Clin Oncol</i>, 2008, 26(12):2013-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/18421054/pubmed\" target=\"_blank\" id=\"18421054\">18421054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandler A, Gray R, Perry MC, et al, &ldquo;Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer,&rdquo; <i>N Engl J Med</i>, 2006, 355(24):2542-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/17167137/pubmed\" target=\"_blank\" id=\"17167137\">17167137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sane DC, Anton L, and Brosnihan KB, &ldquo;Angiogenic Growth Factors and Hypertension,&rdquo; <i>Angengenesis</i>, 2004, 7(3):193-201.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scappaticci FA, Skillings JR, Holden SN, et al, &ldquo;Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated With Chemotherapy and Bevacizumab,&rdquo; <i>J Natl Cancer Inst</i>, 2007, 99(16):1232-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/17686822/pubmed\" target=\"_blank\" id=\"17686822\">17686822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah SR, Gressett Ussery SM, Dowell JE, et al. Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension. <i>Ann Oncol</i>. 2013;24(4):960-965.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/23175623/pubmed\" target=\"_blank\" id=\"23175623\">23175623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. <i>J Clin Oncol</i>. 2014;32(13):1309-1316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/24687829/pubmed\" target=\"_blank\" id=\"24687829\">24687829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. <i>N Engl J Med</i>. 2014;370(8):734-743.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/24552320/pubmed\" target=\"_blank\" id=\"24552320\">24552320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al, &ldquo;Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme,&rdquo; <i>J Clin Oncol</i>, 2007, 25(30):4722-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/17947719/pubmed\" target=\"_blank\" id=\"17947719\">17947719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner AD, Thomssen C, Haerting J, et al, &ldquo;Vascular-Endothelial-Growth-Factor (VEGF) Targeting Therapies for Endocrine Refractory or Resistant Metastatic Breast Cancer,&rdquo; <i>Cochrane Database Syst Rev</i>, 2012, 7:CD008941.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/22786517/pubmed\" target=\"_blank\" id=\"22786517\">22786517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25692915\"></a>Wells JA, Glassman AR, Ayala AR, et al, &ldquo;Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Diabetic Retinopathy Clinical Research Network,&rdquo; <i>N Engl J Med</i>. 2015;372(13):1193-1203. doi: 10.1056/NEJMoa1414264.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/25692915/pubmed\" target=\"_blank\" id=\"25692915\">25692915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29141164\"></a>Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. <i>N Engl J Med</i>. 2017;377(20):1954-1963.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/29141164/pubmed\" target=\"_blank\" id=\"29141164\">29141164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang JC, Haworth L, Sherry RM, et al, &ldquo;A Randomized Trial of Bevacizumab, An Antivascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer,&rdquo; <i>N Engl J Med</i>, 2003, 349(5):427-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/12890841/pubmed\" target=\"_blank\" id=\"12890841\">12890841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26719230\"></a>Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial [Erratum in: <i>Lancet</i>. 2016;387(10026):e24]. <i>Lancet</i>. 2016;387(10026):1405-1414.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/26719230/pubmed\" target=\"_blank\" id=\"26719230\">26719230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhu J, Sharma DB, Gray SW, et al, &ldquo;Carboplatin and Paclitaxel With vs Without Bevacizumab in Older Patients With Advanced Non-Small Cell Lung Cancer,&rdquo; <i>JAMA,</i> 2012, 307(15):1593-601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bevacizumab-including-biosimilars-of-bevacizumab-drug-information/abstract-text/22511687/pubmed\" target=\"_blank\" id=\"22511687\">22511687</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8683 Version 162.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708647\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F141002\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F3422982\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F141022\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F141004\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991321\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988665\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50753376\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51073558\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51073559\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F141005\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F141023\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F140982\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F140970\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50694899\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50606126\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F140985\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F140984\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475200\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2110715\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F140975\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F140988\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F140973\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298861\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F140976\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F140991\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F140992\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F140980\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F140972\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F140987\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51154010\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F140990\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F140993\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8683|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-patient-drug-information\" class=\"drug drug_patient\">Bevacizumab (including biosimilars of bevacizumab): Patient drug information</a></li><li><a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">Bevacizumab (including biosimilars of bevacizumab): Pediatric drug information</a></li></ul></div></div>","javascript":null}